Invest in Replimune Group Inc (REPL) Stock with the prospect of future returns

Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed […]

It is likely that Replimune Group Inc (REPL) Stock will grow up

Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed […]

Don’t be afraid of Replimune Group Inc (REPL) Stock despite uncertainty and doubt

Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed […]

Replimune Group Inc (REPL) Stock Is Emerging from the Clouds

Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed […]

A Tale from the Dusty Corner: Replimune Group Inc (REPL) Stock

Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed […]

Is Replimune Group Inc (REPL) Stock A Better Investment Than Its Rivals?

Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed […]

Replimune Group Inc (REPL) Stock Is Looking Attractive

Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed […]

Are Options A Good Investment Right Now? Replimune Group Inc (REPL) Stock

Piper Sandler raised the price target for the Replimune Group Inc (NASDAQ:REPL) stock to “an Overweight”. The rating was released on April 17, 2023, according to finviz. The research report from BTIG Research has resumed the stock to Buy, with a price target set at $60. The stock was initiated by BTIG Research, who disclosed […]